Literature DB >> 22176145

Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.

Nurcan Üçeyler1, Lan He, Dorothee Schönfeld, Ann-Kathrin Kahn, Karlheinz Reiners, Max J Hilz, Frank Breunig, Claudia Sommer.   

Abstract

Fabry disease (FD) is an X-linked lysosomal storage disorder which may lead to impaired peripheral nerve function, mostly affecting small nerve fibers, and to neuropathic pain. Characteristics of the neuropathy associated with FD and the covariates for its development and temporal course have not been described in a large cohort. We studied small fiber function and morphology in 120 Fabry patients at baseline and in subgroups of these until 4-year follow-up. Baseline neurological (89/120) and electrophysiological (106/120) examination was mostly normal. Quantitative sensory testing revealed impaired cold detection thresholds in 84% of men and 39% of women. Lower leg intraepidermal nerve fiber density (IENFD) was reduced to 46% in Fabry patients compared to controls and to 12.5% in men with impaired renal function. Patients with abnormal IENFD more often had pain. Group means for IENFD did not improve under enzyme replacement therapy (ERT), but IENFD in the back increased under ERT in 4/15 patients with good renal function and clinical improvement. Cutaneous cytokine gene expression did not differ from controls. We conclude that ERT may improve proximal skin innervation in patients with good renal function, but does not protect small fiber function in men with impaired renal function.
© 2011 Peripheral Nerve Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22176145     DOI: 10.1111/j.1529-8027.2011.00365.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  33 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 2.  [Fabry disease : diagnosis and treatment].

Authors:  N Üçeyler; C Sommer
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

3.  Electroneuromyographic Features in Fabry Disease: A Retrospective Review.

Authors:  Çetin Kürşad Akpinar; Hande Türker; Oytun Bayrak; Nilgün Cengiz
Journal:  Noro Psikiyatr Ars       Date:  2015-07-07       Impact factor: 1.339

Review 4.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

5.  Whole-mount imaging of mouse embryo sensory axon projections.

Authors:  Kevin J O'Donovan; Catherine O'Keeffe; Jian Zhong
Journal:  J Vis Exp       Date:  2014-12-09       Impact factor: 1.355

6.  In Patients with an α-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease.

Authors:  Linda van der Tol; Camiel Verhamme; Ivo N van Schaik; Anneke J van der Kooi; Carla E M Hollak; Marieke Biegstraaten
Journal:  JIMD Rep       Date:  2015-11-14

Review 7.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

8.  Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up.

Authors:  L van der Tol; David Cassiman; Gunnar Houge; Mirian C Janssen; Robin H Lachmann; Gabor E Linthorst; Uma Ramaswami; Claudia Sommer; Camilla Tøndel; Michael L West; Frank Weidemann; Frits A Wijburg; Einar Svarstad; Carla Em Hollak; Marieke Biegstraaten
Journal:  JIMD Rep       Date:  2014-09-16

Review 9.  The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.

Authors:  Shannon M Smith; Robert H Dworkin; Dennis C Turk; Ralf Baron; Michael Polydefkis; Irene Tracey; David Borsook; Robert R Edwards; Richard E Harris; Tor D Wager; Lars Arendt-Nielsen; Laurie B Burke; Daniel B Carr; Amy Chappell; John T Farrar; Roy Freeman; Ian Gilron; Veeraindar Goli; Juergen Haeussler; Troels Jensen; Nathaniel P Katz; Jeffrey Kent; Ernest A Kopecky; David A Lee; William Maixner; John D Markman; Justin C McArthur; Michael P McDermott; Lav Parvathenani; Srinivasa N Raja; Bob A Rappaport; Andrew S C Rice; Michael C Rowbotham; Jeffrey K Tobias; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2017-02-27       Impact factor: 5.820

10.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.

Authors:  Karen M Ashe; Eva Budman; Dinesh S Bangari; Craig S Siegel; Jennifer B Nietupski; Bing Wang; Robert J Desnick; Ronald K Scheule; John P Leonard; Seng H Cheng; John Marshall
Journal:  Mol Med       Date:  2015-04-30       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.